--- title: "GeoVax Reports Q1 2026 Net Loss $5.3M, Cash $1.3M, Advances GEO-MVA Phase 3 Plans" type: "News" locale: "en" url: "https://longbridge.com/en/news/286464891.md" description: "GeoVax reported a Q1 2026 net loss of $5.3 million, with cash reserves of $1.3 million. Revenue from government contracts was $0, down from $1.6 million in Q1 2025 due to a contract termination. The company is advancing its GEO-MVA vaccine program and Gedeptin strategies in immuno-oncology. R&D expenses decreased to $3.9 million, while general and administrative expenses fell to $1.4 million. The company plans to initiate a Phase 3 trial for GEO-MVA and continues to focus on Gedeptin's development." datetime: "2026-05-14T20:33:01.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286464891.md) - [en](https://longbridge.com/en/news/286464891.md) - [zh-HK](https://longbridge.com/zh-HK/news/286464891.md) --- # GeoVax Reports Q1 2026 Net Loss $5.3M, Cash $1.3M, Advances GEO-MVA Phase 3 Plans GeoVax reported a net loss of $5.3 million for the quarter ended March 31, 2026, with cash and cash equivalents of approximately $1.3 million as of March 31, 2026. Revenue from government contracts was $0 for Q1 2026 versus $1.6 million in Q1 2025 following a BARDA contract termination. The company reiterated prioritization of its GEO-MVA vaccine program and continued advancement of Gedeptin combination strategies in immuno-oncology. **Financial Highlights** - Net loss: $5.262 million for the three months ended March 31, 2026 (compared with $5.358 million for Q1 2025). - Revenue from government contract: $0 for Q1 2026 (versus $1,637 thousand in Q1 2025). - Research and development expense: $3.904 million for Q1 2026 (down from $5.355 million in Q1 2025). - General and administrative expense: $1.369 million for Q1 2026 (down from $1.687 million in Q1 2025). - Cash and cash equivalents: $1.272 million as of March 31, 2026 (down from $3.086 million at Dec. 31, 2025). **Business Highlights** - GEO-MVA: Advancing under an EMA-aligned expedited regulatory pathway with plans to initiate a Phase 3 immunobridging trial; Phase 3 execution activities underway including CRO selection and trial infrastructure activation. - Manufacturing: Completion and release of cGMP clinical trial material and fill/finish product for clinical use; ongoing work on continuous cell-line manufacturing using the AGE1 platform for future scalable capacity. - Phase 3 study design: Planned enrollment of approximately 500 participants to evaluate neutralizing antibody responses versus an approved MVA comparator using immunobridging endpoints. - Immuno-oncology: Continued advancement of Gedeptin as a gene-directed enzyme prodrug therapy with focus on combination strategies with immune checkpoint inhibitors; exclusive license agreement with Emory University covering combinations with checkpoint inhibitors. - Strategic focus: Prioritizing capital and operations toward GEO-MVA while maintaining Gedeptin development as a strategically important long-term optionality in combination immunotherapies. Original SEC Filing: GeoVax Labs, Inc. \[ GOVX \] - 8-K - May. 14, 2026 **Disclaimer** This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC. ### Related Stocks - [GOVX.US](https://longbridge.com/en/quote/GOVX.US.md) - [GOVXW.US](https://longbridge.com/en/quote/GOVXW.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) ## Related News & Research - [GeoVax Highlights Strategic Importance of Domestic MVA-Based Preparedness Infrastructure Amid Escalating Global Infectious Disease Threats](https://longbridge.com/en/news/286807713.md) - [BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma | ONC Stock News](https://longbridge.com/en/news/286297796.md) - [08:00 ETAvance Clinical Receives Frost & Sullivan's 2026 Global Company of the Year Recognition for Excellence in Biotech CRO Leadership](https://longbridge.com/en/news/286094661.md) - [Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call](https://longbridge.com/en/news/286422585.md) - [Precigen Q1 revenue beats estimates on PAPZIMEOS launch](https://longbridge.com/en/news/286311056.md)